EHS
EHS

FDA expands label for VENCLEXTA to include information about patients with previously-treated CLL

AbbVie, a research-based global biopharmaceutical company, today announced the U.S. Food and Drug Administration has expanded the label for VENCLEXTA® in combination with rituximab to include information about patients with previously-treated chronic lymphocytic leukemia who achieved minimal residual disease (MRD)-negativity in the Phase 3 MURANO trial.

Source link

EHS
Back to top button